Luai Madanat, Teodora Donisan, Dinu V Balanescu, Ahmad Jabri, Ahmad Al-Abdouh, Sam Alsabti, Shuo Li, Mazhed Kheyrbek, Amy Mertens, Ivan Hanson, Simon Dixon
In-stent restenosis (ISR) has been a major limitation in interventional cardiology and constitutes nearly 10 % of all percutaneous coronary interventions in the United States. Drug-eluting stent (DES) restenosis proves particularly difficult to manage and poses a high risk of recurrence and repeat intervention. Intra-coronary brachytherapy (IBT) has been traditionally viewed as a potential treatment modality for ISR. However, its use was hindered by procedural complexity, cost, and the advent of newer-generation DES...
January 30, 2023: Cardiovascular Revascularization Medicine: Including Molecular Interventions